OBJECTIVE: In 2004, Sierra Leone adopted artesunate plus amodiaquine as first-line antimalarial treatment. We evaluated the efficacy of this combination in Kailahun, where a previous study had shown 70.2% efficacy of amodiaquine in monotherapy. METHODS: Method and outcome classification of the study complied with WHO guidelines. Children 6-59 months with uncomplicated malaria were followed-up for 28 days. PCR genotyping was used to distinguish recrudescence from reinfection. Reinfections were reclassified as cured. RESULTS: Of 172 children who were referred to the study clinic, 126 satisfied inclusion criteria and were enrolled. No early treatment failures were reported. The day 14, efficacy was 98.2% (95% CI: 93.8-99.8). Of 65 recurrent parasitaemias analysed by PCR, 17 were recrudescences. The PCR-adjusted day 28 efficacy was 84.5% (95% CI: 76.4-90.7). All true failures occurred in the last 8 days of follow-up. Of 110 children who completed the 28-day follow-up, 54 (49.1%) experienced a novel infection. CONCLUSION: The efficacy of this combination was disappointing. The high reinfection rate suggested little prophylactic effect. In Kailahun a more efficacious combination might be necessary in the future. The efficacy of AS + AQ needs to be monitored in Kailahun and in the other regions of Sierra Leone.
OBJECTIVE: In 2004, Sierra Leone adopted artesunate plus amodiaquine as first-line antimalarial treatment. We evaluated the efficacy of this combination in Kailahun, where a previous study had shown 70.2% efficacy of amodiaquine in monotherapy. METHODS: Method and outcome classification of the study complied with WHO guidelines. Children 6-59 months with uncomplicated malaria were followed-up for 28 days. PCR genotyping was used to distinguish recrudescence from reinfection. Reinfections were reclassified as cured. RESULTS: Of 172 children who were referred to the study clinic, 126 satisfied inclusion criteria and were enrolled. No early treatment failures were reported. The day 14, efficacy was 98.2% (95% CI: 93.8-99.8). Of 65 recurrent parasitaemias analysed by PCR, 17 were recrudescences. The PCR-adjusted day 28 efficacy was 84.5% (95% CI: 76.4-90.7). All true failures occurred in the last 8 days of follow-up. Of 110 children who completed the 28-day follow-up, 54 (49.1%) experienced a novel infection. CONCLUSION: The efficacy of this combination was disappointing. The high reinfection rate suggested little prophylactic effect. In Kailahun a more efficacious combination might be necessary in the future. The efficacy of AS + AQ needs to be monitored in Kailahun and in the other regions of Sierra Leone.
Authors: Martin A Adjuik; Richard Allan; Anupkumar R Anvikar; Elizabeth A Ashley; Mamadou S Ba; Hubert Barennes; Karen I Barnes; Quique Bassat; Elisabeth Baudin; Anders Björkman; François Bompart; Maryline Bonnet; Steffen Borrmann; Philippe Brasseur; Hasifa Bukirwa; Francesco Checchi; Michel Cot; Prabin Dahal; Umberto D'Alessandro; Philippe Deloron; Meghna Desai; Graciela Diap; Abdoulaye A Djimde; Grant Dorsey; Ogobara K Doumbo; Emmanuelle Espié; Jean-Francois Etard; Caterina I Fanello; Jean-François Faucher; Babacar Faye; Jennifer A Flegg; Oumar Gaye; Peter W Gething; Raquel González; Francesco Grandesso; Philippe J Guerin; Jean-Paul Guthmann; Sally Hamour; Armedy Ronny Hasugian; Simon I Hay; Georgina S Humphreys; Vincent Jullien; Elizabeth Juma; Moses R Kamya; Corine Karema; Jean R Kiechel; Peter G Kremsner; Sanjeev Krishna; Valérie Lameyre; Laminou M Ibrahim; Sue J Lee; Bertrand Lell; Andreas Mårtensson; Achille Massougbodji; Hervé Menan; Didier Ménard; Clara Menéndez; Martin Meremikwu; Clarissa Moreira; Carolyn Nabasumba; Michael Nambozi; Jean-Louis Ndiaye; Frederic Nikiema; Christian Nsanzabana; Francine Ntoumi; Bernhards R Ogutu; Piero Olliaro; Lyda Osorio; Jean-Bosco Ouédraogo; Louis K Penali; Mbaye Pene; Loretxu Pinoges; Patrice Piola; Ric N Price; Cally Roper; Philip J Rosenthal; Claude Emile Rwagacondo; Albert Same-Ekobo; Birgit Schramm; Amadou Seck; Bhawna Sharma; Carol Hopkins Sibley; Véronique Sinou; Sodiomon B Sirima; Jeffery J Smith; Frank Smithuis; Fabrice A Somé; Doudou Sow; Sarah G Staedke; Kasia Stepniewska; Todd D Swarthout; Khadime Sylla; Ambrose O Talisuna; Joel Tarning; Walter R J Taylor; Emmanuel A Temu; Julie I Thwing; Emiliana Tjitra; Roger C K Tine; Halidou Tinto; Michel T Vaillant; Neena Valecha; Ingrid Van den Broek; Nicholas J White; Adoke Yeka; Issaka Zongo Journal: BMC Med Date: 2015-03-31 Impact factor: 8.775
Authors: Bernhards Ogutu; Elizabeth Juma; Charles Obonyo; Vincent Jullien; Gwenaelle Carn; Michel Vaillant; Walter Robert John Taylor; Jean-René Kiechel Journal: Malar J Date: 2014-12-16 Impact factor: 2.979
Authors: Sodiomon B Sirima; Alfred B Tiono; Adama Gansané; Amidou Diarra; Amidou Ouédraogo; Amadou T Konaté; Jean René Kiechel; Caroline C Morgan; Piero L Olliaro; Walter R J Taylor Journal: Malar J Date: 2009-03-16 Impact factor: 2.979
Authors: Jean-Paul Guthmann; Francesco Checchi; Ingrid van den Broek; Suna Balkan; Michel van Herp; Eric Comte; Oscar Bernal; Jean-Marie Kindermans; Sarah Venis; Dominique Legros; Philippe J Guerin Journal: PLoS Med Date: 2008-08-05 Impact factor: 11.069
Authors: Elizabeth A Ashley; Loretxu Pinoges; Eleanor Turyakira; Grant Dorsey; Francesco Checchi; Hasifa Bukirwa; Ingrid van den Broek; Issaka Zongo; Pedro Pablo Palma Urruta; Michel van Herp; Suna Balkan; Walter R Taylor; Piero Olliaro; Jean-Paul Guthmann Journal: Malar J Date: 2008-08-09 Impact factor: 2.979